Evidence map›Paper›PMID 38896226›Full record

ArticleAnnals of surgical oncology2024

Comparing Survival of Perihilar Cholangiocarcinoma After R1 Resection Versus Palliative Chemotherapy for Unresected Localized Disease.

Anne-Marleen van Keulen, Stefan Buettner, Pim B Olthof, Heinz-Josef Klümpen, Joris I Erdmann, Laura Izquierdo-Sanchez, Jesus M Banales, Benjamin Goeppert, Stephanie Roessler, Krzysztof Zieniewicz and 23 more

Abstract readComparative Study
In one paragraph

Article in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Existing challenges in the management of cholangiocarcinoma in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  2. Article
  3. Role of Radiation Therapy for Biliary Tract Cancers.Current oncology (Toronto, Ont.) · 2025
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Anne-Marleen van KeulenDepartment of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Stefan BuettnerDepartment of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Pim B OlthofDepartment of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. p.olthof@erasmusmc.nl.
Heinz-Josef KlümpenDepartment of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Joris I ErdmannDepartment of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Laura Izquierdo-SanchezDepartment of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
Jesus M BanalesDepartment of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute, Donostia University Hospital, University of the Basque Country (UPV/EHU), San Sebastian, Spain.
Benjamin GoeppertInstitute of Pathology and Neuropathology, RKH Klinikum Ludwigsburg, Ludwigsburg, Germany.
Stephanie RoesslerInstitute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
Krzysztof ZieniewiczDepartment of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Angela LamarcaDepartment of Oncology - OncoHealth Institute, Fundación Jiménez Díaz University Hospital, Madrid, Spain.
Juan W ValleDepartment of Medical Oncology, The Christie NHS Foundation, Manchester, England.
Adelaida La CastaMedical Oncology Department, OSI Donostialdea/Biodonostia, San Sebastián, Spain.
Frederik J H HoogwaterUniversity Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Matteo DonadonDepartment of Hepatobiliary and General Surgery, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Alexander ScheiterInstitute of Pathology, University of Regensburg, Regensburg, Germany.
Marco MarzioniClinic of Gastroenterology and Hepatology, Universita Politecnica delle Marche, Ancona, Italy.
Jorge AdevaDepartment of Medical Oncology, Hospital Universitario, 12 de Octubre, Madrid, Spain.
Edita KiudelieneDepartment of Gastroenterology, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Jesús María Urman FernándezServicio de Aparato Digestivo, Complejo Hospitalario de Navarra, Pamplona, Navarra, España.
Gianpaolo VidiliDepartment of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
Tudor MocanBabeș-Bolyai University - UBB Med Department, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.
Luca FabrisDepartment of Molecular Medicine, University of Padua School of Medicine, Padua, Italy.
Marcin KrawczykLaboratory of Metabolic Liver Diseases, Medical University of Warsaw, Warsaw, Poland.
Trine FolseraasSection of Gastroenterology and the Norwegian PSC Research Center, Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
Cristina DopazoDepartment of HPB Surgery and Transplants, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Universitat Autónoma de Barcelona, Barcelona, Spain.
Olivier DetryDepartment of Abdominal Surgery and Transplantation, CHU Liege, University of Liege, Liege, Belgium.
Theodor VoiosuGastroenterology Department, Faculty of Medicine, Colentina Clinical Hospital, UMF Carol Davila, Bucharest, Romania.
Viorel ScripcariuUniversity of Medicine and Pharmacy "Gr T Popa", Regional Institute of Oncology, Iasi, Romania.
Francesca BiancanielloDepartment of Translational and Precision Medicine, Sapienza" University of Rome, Rome, Italy.
Chiara BraconiRoyal Marsden NHS Trust, London, Surrey, UK.
Rocio I R MaciasExperimental Hepatology and Drug Targeting (HEVEPHARM) Group, University of Salamanca, IBSAL, CIBERehd, Salamanca, Spain.
Bas Groot KoerkampDepartment of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResection of perihilar cholangiocarcinoma (pCCA) is a complex procedure with a high risk of postoperative mortality and early disease recurrence. The objective of this study was to compare patient characteristics and overall survival (OS) between pCCA patients who underwent an R1 resection and patients with localized pCCA who received palliative systemic chemotherapy.

methodsPatients with a diagnosis of pCCA between 1997-2021 were identified from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) registry. pCCA patients who underwent an R1 resection were compared with patients with localized pCCA (i.e., nonmetastatic) who were ineligible for surgical resection and received palliative systemic chemotherapy. The primary outcome was OS.

resultsOverall, 146 patients in the R1 resection group and 92 patients in the palliative chemotherapy group were included. The palliative chemotherapy group more often underwent biliary drainage (95% vs. 66%, p < 0.001) and had more vascular encasement on imaging (70% vs. 49%, p = 0.012) and CA 19.9 was more frequently >200 IU/L (64 vs. 45%, p = 0.046). Median OS was comparable between both groups (17.1 vs. 16 months, p = 0.06). Overall survival at 5 years after diagnosis was 20.0% with R1 resection and 2.2% with chemotherapy. Type of treatment (i.e., R1 resection or palliative chemotherapy) was not an independent predictor of OS (hazard ratio 0.76, 95% confidence interval 0.55-1.07).

conclusionsPalliative systemic chemotherapy should be considered instead of resection in patients with a high risk of both R1 resection and postoperative mortality.

Indexed as

Bile Duct NeoplasmsKlatskin TumorPalliative CareAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleFollow-Up StudiesHepatectomyHumansMaleMiddle AgedPrognosisRetrospective StudiesSurvival Rate

Identifiers

PMID38896226
PMCPMC11413094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.